BC018465 Activators are a collection of molecules that through various mechanisms, either directly or indirectly, enhance the functional activity of BC018465. For instance, Forskolin, by elevating cAMP levels within the cell, could indirectly promote the activity of BC018465 by PKA-dependent phosphorylation events. Similarly, PMA acts as an activator of PKC, potentially influencing signaling cascades that phosphorylate substrates leading to the activation of BC018465. Ionomycin, by increasing intracellular calcium levels, may activate calcium-dependent kinases, thus enhancing BC018465 activity through phosphorylation. Dibutyryl-cAMP, a cAMP analog, serves to activate cAMP-dependent pathways that might also result in the activation of BC018465 by PKA-mediated phosphorylation. Additionally, Epigallocatechin gallate, as a kinase inhibitor, may lead to an increase in BC018465 activity by preventing the phosphorylation of inhibitory sites, while Sphingosine-1-phosphate can activate specific receptors that initiate signaling cascades, potentially leading to the activation of BC018465.
The activity of BC018465 can also be influenced by modulators of various signaling pathways. LY294002, as a PI3K inhibitor, may indirectly enhance BC018465 activity by impacting AKT signaling and related feedback mechanisms. U0126 and SB203580, which inhibit MEK and p38 MAPK respectively, could shift the signaling dynamics to favor pathways that activate BC018465. Okadaaic acid, by inhibiting protein phosphatases, may prevent the dephosphorylation of proteins, potentially leading to a sustained activation state of BC018465. A23187 and Thapsigargin, both of which disrupt calcium homeostasis by different mechanisms, might activate calcium-dependent signaling cascades that subsequently enhance the activity of BC018465. A23187 acts as an ionophore facilitating calcium influx, while Thapsigargin inhibits the SERCA pump, leading to increased cytosolic calcium levels. Both calcium modulators could thereby potentiate the functional activity of BC018465 through the activation of calcium-dependent kinases. Collectively, these BC018465 Activators, by impacting specific signaling molecules and pathways, provide a multifaceted approach to enhance the activity of BC018465 without the need for direct binding or interaction with the protein itself, demonstrating the complexity and interconnectivity of cellular signaling networks.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator that could lead to the phosphorylation of proteins and signaling cascades that indirectly result in the enhanced activity of BC018465. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $76.00 $265.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium, potentially activating calcium-dependent protein kinases that could phosphorylate and activate BC018465. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $45.00 $130.00 $480.00 $4450.00 | 74 | |
Dibutyryl-cAMP is a membrane-permeable cAMP analog that activates cAMP-dependent pathways, potentially leading to the activation of BC018465 through phosphorylation by PKA. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG is known to inhibit certain protein kinases, which might result in the reduced phosphorylation of inhibitory sites on proteins, possibly leading to the enhanced activity of BC018465. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate is a lipid signaling molecule that activates sphingosine-1-phosphate receptors, potentially initiating signaling cascades that enhance BC018465 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that might alter downstream AKT signaling, potentially relieving negative feedback on pathways that could enhance the activity of BC018465. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that may shift the balance of MAPK signaling, potentially resulting in the increased activity of BC018465 through indirect effects on phosphorylation patterns. | ||||||
SB 202190 | 152121-30-7 | sc-202334 sc-202334A sc-202334B | 1 mg 5 mg 25 mg | $30.00 $125.00 $445.00 | 45 | |
SB203580 is a p38 MAPK inhibitor that can alter the MAPK signaling pathway, potentially leading to the activation of BC018465 by modifying the phosphorylation of related proteins. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic acid is a protein phosphatase inhibitor that could prevent the dephosphorylation of proteins, potentially resulting in the sustained activation of BC018465. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, which could activate calcium-dependent signaling pathways, potentially enhancing the activity of BC018465. | ||||||